Southeastern cancer study group: Breast cancer studies 1972-1982

Richard V. Smalley, Alfred A. Bartolucci, Melvin Moore, Charles Vogel, John Carpenter, Carlos A. Perez, Enrique Velez-Garcia, Victor Marcial, John Lefante, James Wittliff, Alfred A. Ketcham, John Durant

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.

Original languageEnglish
Pages (from-to)1867-1874
Number of pages8
JournalInternational journal of radiation oncology, biology, physics
Volume9
Issue number12
DOIs
StatePublished - Jan 1 1983

Fingerprint

breast
metastasis
cancer
Breast Neoplasms
Neoplasm Metastasis
Survival
Neoplasms
Drug Combinations
liver
lungs
drugs
dosage
Lung
chest
Liver
Thoracic Wall
Therapeutics
Fluorouracil
Doxorubicin
bones

Keywords

  • Adjuvant chemotherapy of primary breast adenocarcinoma
  • CAF
  • CAF-Cameleon
  • Chemotherapy of advanced breast adenocarcinoma
  • CMF
  • CMFVP
  • Postoperative irradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Smalley, R. V., Bartolucci, A. A., Moore, M., Vogel, C., Carpenter, J., Perez, C. A., ... Durant, J. (1983). Southeastern cancer study group: Breast cancer studies 1972-1982. International journal of radiation oncology, biology, physics, 9(12), 1867-1874. https://doi.org/10.1016/0360-3016(83)90354-1

Southeastern cancer study group : Breast cancer studies 1972-1982. / Smalley, Richard V.; Bartolucci, Alfred A.; Moore, Melvin; Vogel, Charles; Carpenter, John; Perez, Carlos A.; Velez-Garcia, Enrique; Marcial, Victor; Lefante, John; Wittliff, James; Ketcham, Alfred A.; Durant, John.

In: International journal of radiation oncology, biology, physics, Vol. 9, No. 12, 01.01.1983, p. 1867-1874.

Research output: Contribution to journalArticle

Smalley, RV, Bartolucci, AA, Moore, M, Vogel, C, Carpenter, J, Perez, CA, Velez-Garcia, E, Marcial, V, Lefante, J, Wittliff, J, Ketcham, AA & Durant, J 1983, 'Southeastern cancer study group: Breast cancer studies 1972-1982', International journal of radiation oncology, biology, physics, vol. 9, no. 12, pp. 1867-1874. https://doi.org/10.1016/0360-3016(83)90354-1
Smalley, Richard V. ; Bartolucci, Alfred A. ; Moore, Melvin ; Vogel, Charles ; Carpenter, John ; Perez, Carlos A. ; Velez-Garcia, Enrique ; Marcial, Victor ; Lefante, John ; Wittliff, James ; Ketcham, Alfred A. ; Durant, John. / Southeastern cancer study group : Breast cancer studies 1972-1982. In: International journal of radiation oncology, biology, physics. 1983 ; Vol. 9, No. 12. pp. 1867-1874.
@article{5211b147b8e74b389466f841e3998c34,
title = "Southeastern cancer study group: Breast cancer studies 1972-1982",
abstract = "During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.",
keywords = "Adjuvant chemotherapy of primary breast adenocarcinoma, CAF, CAF-Cameleon, Chemotherapy of advanced breast adenocarcinoma, CMF, CMFVP, Postoperative irradiation",
author = "Smalley, {Richard V.} and Bartolucci, {Alfred A.} and Melvin Moore and Charles Vogel and John Carpenter and Perez, {Carlos A.} and Enrique Velez-Garcia and Victor Marcial and John Lefante and James Wittliff and Ketcham, {Alfred A.} and John Durant",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0360-3016(83)90354-1",
language = "English",
volume = "9",
pages = "1867--1874",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Southeastern cancer study group

T2 - Breast cancer studies 1972-1982

AU - Smalley, Richard V.

AU - Bartolucci, Alfred A.

AU - Moore, Melvin

AU - Vogel, Charles

AU - Carpenter, John

AU - Perez, Carlos A.

AU - Velez-Garcia, Enrique

AU - Marcial, Victor

AU - Lefante, John

AU - Wittliff, James

AU - Ketcham, Alfred A.

AU - Durant, John

PY - 1983/1/1

Y1 - 1983/1/1

N2 - During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.

AB - During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.

KW - Adjuvant chemotherapy of primary breast adenocarcinoma

KW - CAF

KW - CAF-Cameleon

KW - Chemotherapy of advanced breast adenocarcinoma

KW - CMF

KW - CMFVP

KW - Postoperative irradiation

UR - http://www.scopus.com/inward/record.url?scp=0021040215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021040215&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(83)90354-1

DO - 10.1016/0360-3016(83)90354-1

M3 - Article

C2 - 6607245

AN - SCOPUS:0021040215

VL - 9

SP - 1867

EP - 1874

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 12

ER -